Home / Policies & Legislation / Further problems for Indian manufacturing sites

Further problems for Indian manufacturing sites Posted 11/12/2015

The US Food and Drug Administration (FDA) has written to Sandoz after identifying significant violations of current good manufacturing practice (cGMP) at two of the company’s manufacturing sites in western India, Turbhe and Kalwa. Turbhe is an Active Pharmaceutical Ingredient and Finished Dosage Manufacturing Site, Kalwha is a Finished Dosage Manufacturing Site.

According to FDA regulations, drug products leaving these sites are adulterated. ‘Methods used in, or facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with, cGMP,’ reads a letter from FDA written on 22 October 2015.

FDA first alerted Sandoz to these cGMP violations in August 2014 and has now conducted a detailed review of the firm’s responses received between September 2014 and August 2015. The responses received from Sandoz over that time have been branded inadequate.

FDA has called on Sandoz to describe the ‘corrective actions’ they will take, such as contacting customers, recalling product, conducting additional testing and/or adding lots to stability programmes to assure stability, or monitoring complaints. FDA has also asked Sandoz to describe the ‘preventive actions’ they will take, such as revising procedures, implementing new controls, training or re-training personnel, or other steps to prevent the recurrence of cGMP violations, including breaches of data integrity.

Sandoz was given 15 working days from the receipt of this letter to notify FDA of the specific steps they have taken to ‘correct and prevent the recurrence of deviation’.

FDA has said it may withhold approval of any new applications or supplements which list Sandoz as a drug product manufacturer until all corrections are completed and the agency confirms corrections of the violations and compliance with cGMP.

FDA keeps a close eye on Indian drug manufacturing sites and is known to have banned 30 sites since 2013 [1, 2]. Further reports are in danger of damaging the reputation of the industry, an important supplier of more affordable generics.

Related article
US will continue to buy Indian generics despite quality concerns

Recalls call into question metoprolol generics

References
1.    GaBI Online - Generics and Biosimilars Initiative. FDA issues warning letters to Indian firms [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Dec 11]. Available from: www.gabionline.net/Policies-Legislation/FDA-issues-warning-letters-to-Indian-firms
2.    GaBI Online - Generics and Biosimilars Initiative. FDA issues more warnings to Indian firms [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Dec 11]. Available from: www.gabionline.net/Policies-Legislation/FDA-issues-more-warnings-to-Indian-firms

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved. 

Source: US FDA

Comments (0)